LY75 (Lymphocyte Antigen 75)

This study establishes a novel combinatorial strategy utilizing CD205-targeted, tumor cell-derived NVs as a DC vaccine to effectively reprogram the immunosuppressive TME. CAR-T + Vac therapy significantly enhances CAR-T cell infiltration and antitumor efficacy against lung cancer, providing a versatile and promising platform for advancing solid tumor immunotherapy.

Our study identified 37 potential lymphoma drug targets, emphasizing FCRL3 and LY9 as valuable therapeutic candidates, and amiodarone and chrysin in clinical translational application.

LY75 promoter methylation identifies patients at high risk of recurrences or metastases, independent of conventional prognostic parameters. This marker could help refine patient selection for sentinel node biopsies, imaging, (neo)adjuvant treatment, and closer monitoring, ultimately leading to improved clinical outcomes.

Through multi-omics analysis, we identified new potential therapeutic targets for papillary thyroid carcinoma and investigated their possible underlying mechanisms affecting PTC.

The activated DCs further activate the body's cytotoxic T cells (CTLs), thereby exerting anti-tumor effects. This study will provide a new idea for the construction of tumor nanovaccines.

Finally, the constructed nomogram model could significantly predict the prognosis of colorectal cancer. This study identifies eight prognostic signature genes associated with MSI and immune infiltration in colon cancer, suggesting their potential for predicting prognostic risk.

We detected significantly higher levels of dermal dendritic cells (CD205+CD11c+), granulocytes (Ly6G+), but macrophages (F4-80+) recruited to the infected tongues of CBD-treated females. Our findings suggest that CBD may play a role in promoting MmuPV1 persistence in the oral cavity.

Our study identified several druggable genes associated with leukemia risk and provided new insights into the etiology and drug development of leukemia. We also found that genetically predicted higher leukocyte telomere length increased LL risk and its potential mechanism of action.

The genetic predisposition to early-onset OC appears to be a heterogeneous and complex process that goes beyond the traditional Mendelian monogenic understanding of hereditary cancer predisposition, with a significant role of the immune system. We speculate that rather a cumulative overall GPV burden than specific GPV may potentially increase OC risk, concomitantly with reduced HLA diversity.

In mouse tumor models, the calcium nanoparticles enhanced the antitumor immune response and augmented the efficacy of both radiotherapy and chemotherapy without introducing additional toxicity. Our study introduces a safe nanoparticle immunomodulator with potential widespread applications in cancer therapy.

P2, N=50, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

P1, N=200, Recruiting, Oxford BioTherapeutics Ltd | N=150 --> 200 | Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2026